LLY250103C510000
- 0.00
- 0.000.00%
Eli Lilly and Co Newsroom
FDA Issues First Draft Guidance on Use of AI in Drug, Medical Device Development
BofA's Growth 10 Screen as January 2025 Trade Revs up
Healthcare Sector's 2024 Gainers and Losers: Intuitive Surgical, Boston Scientific Tops Chart
Is Eli Lilly and Company (NYSE:LLY) Among Israel Englander's Top Stock Picks Heading Into 2025?
J.P. Morgan Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,100
Express News | Orbis Medicines: Financing Led by Nea With Participation From Eli Lilly, Export and Investment Fund of Denmark, Novo Holdings, Forbion, Others
Israel Englander's Millennium Management Dumps Nvidia, Loads Up On Broadcom — Here's What The $70 Billion Hedge Fund Sees
Eli Lilly's (NYSE:LLY) Dividend Will Be Increased To $1.50
Novo Nordisk Seeks to Block Compounded Victoza
Smart Money Is Betting Big In LLY Options
Viking Therapeutics Among Potential Buyout Candidates: Oppenheimer
Jim Cramer Says Lazard Is 'Really Inexpensive,' Recommends Buying This Tech Stock
Eli Lilly and Company (LLY) Is Attracting Investor Attention: Here Is What You Should Know
Eli Lilly Joins FDA Lawsuit Over Compounded Obesity Drugs, Seeks 'Swift End' And 'To Protect Its Interests'
Express News | Eli Lilly and Co seeks to intervene in the lawsuit between the USA Food and Drug Administration (FDA) and numerous pharmacists regarding whether there is still a supply shortage of Eli Lilly's weight-loss drug Tirzepatide. Eli Lilly claims that all of its
Don't Buy Weight-Loss Medication From Unauthorized Sources, UK Health Agency Warns About Risks
Weight Loss Drugs Can Cut Grocery Spending by up to 9%: Study
Insurance is not covered, supply shortages, rampant generic drugs, slow new drug development, and new weight-loss medications still face challenges.
New GLP-1 weight loss drugs are not only changing the lives of obese populations but also creating billions of dollars in revenue for pharmaceutical companies like Eli Lilly and Co and Novo-Nordisk A/S. However, analysis indicates that weight loss drugs currently face some challenges in the USA: there is the risk of insurance companies refusing to pay, and ongoing supply shortages have created opportunities for lower-priced generic drugs. Additionally, it remains uncertain whether pharmaceutical companies can truly develop better weight loss medications and what the new U.S. government's attitude toward weight loss drugs will be.
Jefferies Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $994
Eli Lilly Stock Upgraded to "Buy" as Analysts Boost Price Target to $1,250